• Knowledge Hubs
    • Conference Coverage
      • Roundtables
        • The Uromigos
          • Uromigos Live 2024
            • AUC3
              • Calendar
                Main Logo

                ASCO 2024: The Role of ctDNA in the TheraP Trial - LuPSMA vs Cabazitaxel in CRPC

                By The Uromigos - Last Updated: July 10, 2024

                Dr. Alex Wyatt from Vancouver Prostate Centre describes the predictive capabilities of ctDNA in determining outcomes in the TheraP trial.

                Post Tags:Uromigos-ASCO

                Related Podcasts

                Episode 398: Reflections on the Felix Feng Symposium at ASCO GU
                Episode 397: APCCC Diagnostics Conference Recap
                Uromigos-Prostate Cancer
                Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025
                Uromigos-Prostate Cancer
                Episode 393: ASCO GU 2025 Review Podcast
                Episode 392: ASCO GU 2025 - HIF Inhibition With Casdatifan in Refractory RCC
                Uromigos-Kidney Cancer

              • 630 Madison Ave.

                Manalapan, NJ 07726

                • About

                About Us

                Contributors and Partners

                Editorial Policy

                Advertising

                Connect

                eNewsletters

                Calendar

                Contact Us

                Contribute

                Our Network

                MashupMD

                Cancer Nursing Today

                Urban Health Today

                Blood Cancers Today

                DocWire News

                Formedics logo© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

                Terms of Use | Privacy Policy |